

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A method for treating proliferative skin diseases comprising the administration of an effective amount of a gel comprising about 0.01% to about 2% w/v tazarotene gel and:

(a) water;

(b) edetate disodium;

(c) ascorbic acid;

(d) Carbomer 934P;

(e) Poloxamer 407;

(f) polyethylene glycol;

(g) Polysorbate 40;

(h) hexylene glycol;

(i) butylated hydroxytoluene;

(j) butylated hydroxyanisole;

(k) benzyl alcohol; and

(l) tromethamine

and an effective amount of a corticosteroid, wherein said corticosteroid is alclometasone dipropionate and/or betamethasone valerate.

Claims 2-5. (Cancelled)

6. (Currently Amended) A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of gel comprising about 0.01% to about 2% w/v tazarotene and:

- (a) water;
- (b) edetate disodium;
- (c) ascorbic acid;
- (d) Carbomer 934P;
- (e) Poloxamer 407;
- (f) polyethylene glycol;
- (g) Polysorbate 40;
- (h) hexylene glycol;
- (i) butylated hydroxytoluene;
- (j) butylated hydroxyanisole;
- (k) benzyl alcohol; and
- (l) tromethamine

and an effective amount of a corticosteroid wherein said corticosteroid is alclometasone dipropionate and/or betamethasone valerate.

Claims 7-10. (Cancelled)

11. (Previously Amended) The method of claim 6 wherein tazarotene is administered once daily in the evening and the corticosteroid is administered once daily in the morning.

12. (Previously Amended) The method of Claim 6 wherein the tazarotene is applied as a 1.0 % gel.

13. (Previously Amended) The method of Claim 6 wherein the tazarotene is applied as a 1.0 % cream.

14. (Canceled)